Skip to main content
Smart Investors Daily
IV

NASDAQ · IVA

Inventiva S.A.

Healthcare · Biotechnology

$3.14

Down-$0.31 (-8.99%)

Updated Nov 21, 2026, 7:55 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
233.4M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$2.82 – $7.29
Volume
3.02M
Avg. volume
247.07K

Price performance · IVA

IVA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

IVA closed at $3.14 after 21 trading sessions, down 15.36% for the selected period.

Last close
$3.14
Period change
-15.36%
Period low
$3.14
Period high
$4.03
Daily close
View OHLC price history
IVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$3.44$3.44$3.13$3.143.02M
Nov 19, 2026$3.45$3.675$3.42$3.453.06M
Nov 18, 2026$3.18$3.41$3.12$3.393.54M
Nov 17, 2026$3.34$3.34$3.105$3.222.05M
Nov 16, 2026$3.81$3.828$3.295$3.322.47M
Nov 13, 2026$3.86$3.88$3.67$3.683.32M
Nov 12, 2026$3.98$4.105$3.87$3.882.5M
Nov 11, 2026$3.88$4.06$3.80$4.012.37M
Nov 10, 2026$3.80$3.99$3.77$3.952.26M
Nov 9, 2026$3.81$3.8987$3.69$3.841.57M
Nov 6, 2026$3.63$3.825$3.60$3.802.22M
Nov 5, 2026$3.96$3.96$3.615$3.632.54M
Nov 4, 2026$4.18$4.27$3.855$3.871.58M
Nov 3, 2026$3.80$4.165$3.78$4.034.07M
Nov 2, 2026$3.62$3.9899$3.551$3.833.25M
Oct 30, 2026$3.69$3.76$3.585$3.651.73M
Oct 29, 2026$3.75$3.8599$3.68$3.731.44M
Oct 28, 2026$3.69$3.77$3.65$3.71946.95K
Oct 27, 2026$3.77$3.855$3.625$3.6851.78M
Oct 26, 2026$3.67$3.865$3.64$3.663.33M
Oct 23, 2026$3.53$3.76$3.47$3.714.71M

Latest IVA news

The latest Smart Investors Daily articles mentioning IVA.

IVA research

Overview

Company profile and research snapshot.

Company profile

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.33
Implied upside
—
Analysts
—
IVA recent ratings
DateFirmRatingTarget
Sep 16, 2026PIPER SANDLER COMPANIESOverweight—
Sep 15, 2026GUGGENHEIM SECURITIES LLCBuy—
Sep 3, 2026KBC SECURITIESBuy—
Aug 13, 2026CANTOR FITZGERALDOverweight—
Aug 1, 2026TD COWENBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?

Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack. Since the thesis was published on July 31st, IVA shares have pulled back as investors weigh the upcoming Phase 3 NATiV3 results and the company’s financing needs, but the trial results could still shape the drug’s future. […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.